C4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial - AZN News | RalliesC4X Discovery to receive $13 million AstraZeneca milestone as NRF2 drug enters Phase I trial
A
AZN• AstraZeneca milestone triggered by Phase I progress
- C4X Discovery to receive a $13 million milestone payment from AstraZeneca on 4 September 2026.
- Payment triggered by AstraZeneca advancing AZD4916, an oral NRF2 activator licensed from C4X Discovery, into Phase I.
- Deal signed in November 2022 provides up to $400 million in preclinical and clinical milestones.
- Agreement also includes tiered mid-single digit royalties on future sales.
ZS
•
